For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Placebo | Buprenorphine will be given, with 2 capsules of placebo in the morning and 2 take-home capsules of placebo in the evening | None | None | 0 | 14 | 4 | 14 | View |
| Gabapentin | Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night. | None | None | 0 | 16 | 10 | 16 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Dizziness/Lightheadedness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| nausea/vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Sleepiness/Fatigue/Somnulence | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |
| Vivid, disturbing dreams, nightmares | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |
| muscle twitches/cramps | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Insomnia | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |